A significant reduction in both CD8+ and CD4+ T cell infiltration was apparent in RAC1A159V tumors, further suggesting a shift toward a cold tumor caused by the RAC1A159V mutation that potentially contributes to the diminished responsiveness to anti-PD1 treatment (Fig. 2I). The gene discussed is CD4; the disease is neoplasm.